Category: Ageing, Longevity and disease.

Scientific and medical journal publications and studies in ageing and longevity.

Health Hacker Australia > The Science > Ageing, Longevity and disease.
Can Anti-Aging Research Keep Us Healthy in the Long Run?

Can Anti-Aging Research Keep Us Healthy in the Long Run?

Searching for the fountain of eternal youth has been the dream of humanity for millennia. While this is still in the realms of science fiction, anti-aging companies are hoping to tackle aging-related diseases by targeting the underlying biology.

A cell-killing strategy to slow aging passed its first test this year – MIT Technology Review

A cell-killing strategy to slow aging passed its first test this year – MIT Technology Review

https://www.technologyreview.com/s/612943/a-cell-killing-strategy-to-slow-aging-passed-its-first-test-this-year/?utm_medium=tr_social&utm_source=facebook&utm_campaign=site_visitor.unpaid.engagement&fbclid=IwAR222QRKzlC7S9VIkAmTwpMC687xvXe7BuLdTMxtRvnTB0MnircvKrefNGI
Patients took two pills that Kirkland and his colleagues believed could selectively get rid of aged cells: the leukemia drug dasatinib and a supplement called quercetin.
Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study | npj Aging and Mechanisms of Disease

Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study | npj Aging and Mechanisms of Disease

https://www.nature.com/articles/s41514-017-0016-9?fbclid=IwAR3_q3CK4fHkOygi2rVWo-NtoUoDpwDOdZ6I4kf3BWCdoorU0Csx8BfuA_0

Will extending human lifespan cause us problems with population?

Will extending human lifespan cause us problems with population?

Well maybe not. Many of the models show that the population will naturally plateau.

In some regions mortality is outstripping birth rate already.

https://www.pewresearch.org/fact-tank/2019/06/17/worlds-population-is-projected-to-nearly-stop-growing-by-the-end-of-the-century/

A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis

A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis

Activation of Sirtuin (silent mating type information regulation 2 homolog) 1, or SIRT1, is an unexplored therapeutic approach for treatment of inflammatory diseases. We randomized 40 patients with moderate-to-severe psoriasis (4:1) to three escalating doses of SRT2104, a selective activator of SIRT1, or placebo. Across all SRT2104 groups, 35% of patients (p<0.0001) achieved good to excellent histological improvement based on skin biopsies taken at baseline and day 84 but was not consistently in agreement with PASI. Improvement in histology was associated with modulation of IL-17 and TNF-α signaling pathways and keratinocyte differentiation target genes. 27 subjects (69%) across all treatment groups, including placebo, experienced at least one treatment emergent adverse event. The majority of AEs were either mild or moderate. Most common were headache (8%), dizziness (8%), upper respiratory tract infection (8%), and psoriatic arthropathy (8%). Average drug exposure increased in a dose-dependent manner for escalating doses of SRT2104 and had high intra-subject variability in exposure (AUC %CV: 51–89%). Given the interesting signals of clinical activity, impact on gene expression and the generally favorable safety profile seen in this study, further investigation of SIRT1 activators for the treatment of psoriasis is warranted. Trial Registration Clinicaltrials.gov NCT01154101

Source: A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis

Nicotinamide mononucleotide protects against β-amyloid oligomer-induced cognitive impairment and neuronal death. – PubMed – NCBI

Nicotinamide mononucleotide protects against β-amyloid oligomer-induced cognitive impairment and neuronal death. – PubMed – NCBI

Brain Res. 2016 Jul 15;1643:1-9. doi: 10.1016/j.brainres.2016.04.060. Epub 2016 Apr 26. Research Support, Non-U.S. Gov’t

Source: Nicotinamide mononucleotide protects against β-amyloid oligomer-induced cognitive impairment and neuronal death. – PubMed – NCBI

Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. – PubMed – NCBI

Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. – PubMed – NCBI

Cell Metab. 2011 Oct 5;14(4):528-36. doi: 10.1016/j.cmet.2011.08.014. Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov’t

Source: Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. – PubMed – NCBI

Nicotinamide mononucleotide | C11H15N2O8P – PubChem

Nicotinamide mononucleotide | C11H15N2O8P – PubChem

Nicotinamide mononucleotide | C11H15N2O8P | CID 14180 – structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.

Source: Nicotinamide mononucleotide | C11H15N2O8P – PubChem

Aging | Rapamycin retards epigenetic ageing of keratinocytes independently of its effects on replicative senescence, proliferation and differentiation – Full Text

Aging | Rapamycin retards epigenetic ageing of keratinocytes independently of its effects on replicative senescence, proliferation and differentiation – Full Text

Aging | doi:10.18632/aging.101976. Steve Horvath, Ake T. Lu, Howard Cohen, Ken Raj

Source: Aging | Rapamycin retards epigenetic ageing of keratinocytes independently of its effects on replicative senescence, proliferation and differentiation – Full Text